Treats obsessive compulsive disorder (OCD). ANDA 217024, held by Annora Pharma. Fluvoxamine Maleate.
As of Nov 16, 2026, ANDA 217024 (Fluvoxamine Maleate), held by Annora Pharma, was first approved by FDA on Jul 30, 2025, with 0 approved supplements and 0 published complete response letters.
Fluvoxamine maleate extended-release capsules are a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of obsessive compulsive disorder (OCD). Efficacy was demonstrated in:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 30, 2025 | Original application | Approved | None posted |
| Fluvoxamine Maleate100MG · capsule, extended release;oral | Fluvoxamine Maleate | Rx |
| Fluvoxamine Maleate150MG · capsule, extended release;oral | Fluvoxamine Maleate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters